Company
EnCellin
Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2016
- encellin.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Encellin’s technology and patient-driven approach combines a novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders.
Funding snapshot
- Total raised
- $15.8MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Undisclosed, $9.9M2023-12-15
Funding rounds
- Round, 2023
- $9.9M2023-12-15, Company stated
- Round, 2023
- $9.9M2023-09-20, SEC form D sold, 26 investors
- Seed
- $5.9M2021-08-05, Company stated
- Round, 2019
- $2.1M2019-06-28, SEC form D sold, 7 investors
Products
- Hardware
- Encapsulated Cell Replacement Therapy (ENCRT)
- Web
- ENCRT
Loading relationship preview